Literature DB >> 29183729

miR-596 Modulates Melanoma Growth by Regulating Cell Survival and Death.

Szu-Mam Liu1, Chen-Huan Lin1, Jean Lu2, In-Yu Lin1, Mu-Shiun Tsai3, Ming-Hong Chen4, Nianhan Ma5.   

Abstract

Tumors grow because cancer cells lack the ability to balance cell survival and death signaling pathways. miR-596, a microRNA located at the 8p23.3 locus, has been shown by the TCGA-Assembler to be deleted in a significant number of melanoma samples. Here, we also validated the low levels of miR-596 in melanoma compared to tissue nevi, and Kaplan-Meier curve analysis revealed that low miR-596 expression was associated with worse overall survival. Moreover, we showed that miR-596 overexpression effectively inhibited MAPK/ERK signaling, cell proliferation, migration, and invasion and increased the cell apoptosis of melanoma cells. In addition, we found that miR-596 directly targets MEK1 and two apoptotic proteins, MCL1, and BCL2L1, in melanoma cells. Our findings indicated that miR-596 is an important miRNA that both negatively regulates the MAPK/ERK signaling pathway by targeting MEK1 and modulates the apoptosis pathway by targeting MCL1 and BCL2L1, suggesting that miR-596 could be a therapeutic candidate for treating melanoma, and a prognostic factor for melanoma patients.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29183729     DOI: 10.1016/j.jid.2017.11.016

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.

Authors:  Justin Chen; Maria K Haanpää; Joshua J Gruber; Natalie Jäger; James M Ford; Michael P Snyder
Journal:  Clin Cancer Res       Date:  2019-06-07       Impact factor: 12.531

2.  Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.

Authors:  Heng Wang; Chuangye Wei; Peng Pan; Fengfeng Yuan; Jiancheng Cheng
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 3.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

4.  Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1.

Authors:  Junrong Wang; Weimin Ding; Yingke Xu; Enfu Tao; Miaojun Mo; Wei Xu; Xu Cai; Xiaomin Chen; Junhui Yuan; Xiuying Wu
Journal:  Aging (Albany NY)       Date:  2020-03-12       Impact factor: 5.682

5.  MiR-596 activated by EP300 controls the tumorigenesis in epithelial ovarian cancer by declining BRD4 and KPNA4.

Authors:  Deying Wang; Yulan Cui; Aili Xu; Lin Zhao; Peiling Li
Journal:  Cancer Cell Int       Date:  2020-09-11       Impact factor: 5.722

Review 6.  Targeting MCL-1 in cancer: current status and perspectives.

Authors:  Haolan Wang; Ming Guo; Hudie Wei; Yongheng Chen
Journal:  J Hematol Oncol       Date:  2021-04-21       Impact factor: 17.388

7.  Plasma exosomal miR-596: a novel biomarker predicts survival in patients with idiopathic pulmonary artery hypertension.

Authors:  Yang Huang; Zuo-Gang Wang; Liang Tang; Su-Gang Gong; Yuan-Yuan Sun; Lan Wang; Rong Jiang; Wen-Hui Wu; Ci-Jun Luo; Jie Zhang; Xiao-Jun Yang; Jin-Ling Li; Xun-Tao Yuan; Qin-Hua Zhao; Ping Yuan
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

8.  CircularRNA_0119872 regulates the microRNA-582-3p/E2F transcription factor 3 pathway to promote the progression of malignant melanoma.

Authors:  Jinlong Qu; Chunying Yuan; Qi Jia; Mengwei Sun; Min Jiang; Fuguang Zuo
Journal:  Clinics (Sao Paulo)       Date:  2021-10-11       Impact factor: 2.365

9.  MiR-596 inhibits osteoblastic differentiation and cell proliferation by targeting Smad3 in steroid-induced osteonecrosis of femoral head.

Authors:  Ligong Fu; Huawei Liu; Weijun Lei
Journal:  J Orthop Surg Res       Date:  2020-05-14       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.